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Objective: As only the free non-protein bound concentration of an antiepileptic drug (AED) crosses 
the blood brain barrier, entering the brain and producing an antiepileptic effect, knowledge and 
measurement of the free drug fraction is important. Such data are sparse, particularly for newer 
AEDs and have arisen from the use of disparate methodologies and setting over the last six decades. 
We report on the protein binding of 25 AEDs available for clinical use, along with two 
pharmacologically active metabolites (carbamazepine-epoxide and N-desmethyl clobazam), using 
standardized methodology and under set conditions. 
Methods: The protein binding of the various AEDs was undertaken in sera of 278 patients. 
Separation of the free non-protein bound component was achieved by using ultracentrifugation 
(Amicon Centrifree Micropartition System) under set conditions: 500 µL serum volume; 
centrifugation at 1,000g for 15 minutes and at 25°C). Free and total AED concentrations were 
measured by use of fully validated liquid chromatography/mass spectroscopy techniques.  
Results: Gabapentin and pregabalin are non-protein bound whilst highly bound AEDs (≥ 88%) 
include clobazam, clonazepam, perampanel, retigabine, stiripentol, tiagabine and valproic acid as 
well as the N-desmethyl-clobazam (89%) metabolite. The minimally bound drugs (<22%) include 
ethosuximide (21.8%), lacosamide (14.0%), levetiracetam (3.4%), topiramate (19.5%) and 
vigabatrin (17.1%). Ten of the 25 AEDs exhibit moderate protein binding (mean range, 27.7-
74.8%).  
Significance: These data provide a comprehensive comparison of serum protein binding of all 
available AEDs including the metabolites, carbamazepine-epoxide and N-desmethyl-clobazam. 












 Epilepsy treatment can be optimized by knowledge of the free fraction of AEDs because 
only the free non-protein bound component enters the brain so as to exert an antiepileptic 
effect   
 Using a standardised methodology we measured the free fraction of 25 licensed AEDs, 
including the metabolites, carbamazepine-epoxide and N-desmethyl-clobazam    
 The highly bound AEDs (≥ 88%) include clobazam, clonazepam, perampanel, retigabine, 
stiripentol, tiagabine and valproic acid as well as the N-desmethyl-clobazam (89%) 
metabolite 
 The minimally bound drugs (<22%) include ethosuximide, lacosamide, levetiracetam, 
topiramate and vigabatrin 
  Ten of the 25 AEDs, including the carbamazepine-epoxide metabolite (49.8%) exhibit 
moderate protein binding (mean range, 27.7-74.8%) 
 Gabapentin and pregabalin are not protein bound (0%) 
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Introduction 
 The serum protein binding of antiepileptic drugs (AEDs) has a significant impact on their 
effect as only the free unbound drug is available to pass the blood brain barrier, entering the brain 
and therefore producing an antiepileptic effect. When binding occurs, typically, AEDs bind 
reversibly to albumin, the most abundant blood protein, but some binding can occur on α1-acid 
glycoprotein. AEDs that are considered to be highly bound (i.e. >90%) include phenytoin, valproic 
acid, tiagabine, perampanel and stiripentol whilst AEDs considered not to be bound include 
ethosuximide, gabapentin, levetiracetam, pregabalin and vigabatrin (Tables 1-3). The other AEDs 
are reported to be bound to various degrees between these values. 
 Routine AED therapeutic drug monitoring (TDM) entails the measurement of serum (or 
plasma) total concentrations. In most clinical settings, where the relationship between the bound 
and free unbound components is constant, this approach will suffice.1 There are, however, clinical 
settings in which free drug concentrations are significantly higher than expected from total drug 
concentration measurements; this is particularly the case for those highly bound AEDs.2  Settings in 
which this can occur include: uremia, hepatic diseases  hypoalbuminemia (e.g. children, the elderly, 
during pregnancy, post surgery, burns patients, undernourished and HIV infection); and suspected 
plasma protein binding interactions whereby strongly bound drugs compete.3-6       
 Examples of highly protein bound AED which are susceptible to protein binding impairment 
are phenytoin and valproic acid. In the case of phenytoin, the free fraction of phenytoin increases, 
which is followed by increased clearance compensation. The net result is a decreased total 
concentration level, but normal or higher free levels. Valproic acid shows saturable binding to 
serum proteins and it may cause binding displacement of other highly protein bound drugs, which 
does occur when co-administered with phenytoin and also tiagabine.5,6 TDM of total concentration 
in this setting would be misleading and only the measurement of free drug serum concentration 
would relate to the drug’s toxicity and efficacy.5    
Measurement of free drug concentrations can only be undertaken after separation from that 
that is protein bound and various methodologies have been described including microdialysis, 
equilibrium dialysis, ultrafiltration, ultracentrifugation and gel filtration and each have their 
advantages and disadvantages.4 The most frequently used methods are equilibrium dialysis, used in 
basic/experimental research and considered to be the gold standard method; microdialysis, used for 
in vivo studies in humans and animals; and ultrafiltration, the method of choice in a clinical 
laboratory which provides a routine TDM service because it is convenient to use.4 Ultrafiltration 
requires care as ultrafiltrate volume, temperature and ultrafiltration device, centrifugation time and 
membrane used can impact on the concentration measurement.7,8  
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Monitoring of free levels is cumbersome and technically challenging, as it requires 
separation of the free fraction and measurement capabilities may not be sensitive enough to measure 
very low concentrations typically encountered. Ultrafiltration is the preferred method to isolate the 
free drug, as it is relatively simple, adsorption problems have been overcome with technological 
improvement9,10 and precautions can be taken to prevent temperature dependent effects.18,11 
Immunoassays and chromatographic methods are used for AED measurements in TDM units. High 
performance liquid chromatography (HPLC) and tandem mass spectrometer (MS/MS) coupled 
together (LC-MS/MS) is the most popular method as it can reliably detect and quantify many 
different drugs in a single assay.9,10  
Currently there are at least 25 AEDs licensed for clinical use and these are categorized into 
first generation, second generation and third generation AEDs (Tables 1-3). Overall, there have 
been numerous reports describing the serum protein binding of the first generation AEDs and in 
particular carbamazepine, phenytoin and valproic acid. There is sparse data for the binding of the 
pharmacologically active metabolite of carbamazepine (carbamazepine-epoxide), clobazam, 
clonazepam, phenobarbital and primidone (Table 1). There are no reports of the binding 
characteristics of the active metabolite of clobazam (N-desmethyl-clobazam); indeed there is not 
even a mention of its binding in the clobazam summary of product characteristics (SPCs). 
Carbamazepine, phenytoin and valproic acid have more available data as they were the most 
substantially protein bound AEDs and therefore susceptible to protein binding displacement 
interactions. Valproic acid also exhibited non-linear pharmacokinetic characteristics consequent to 
saturable protein binding and this phenomenon attracted many investigations.10,12 Regarding the 
second and third generation  AEDs, there have been few protein binding studies reported (Tables 2 
and 3) and, for some (e.g. brivaracetam, felbamate, perampanel, pregabalin, retigabine, rufinamide 
stiripentol, tiagabine and vigabatrin) the only data available are those reported in SPCs which are 
universally vague and lack details as to methodology or methodology conditions. Perhaps another 
reason for the lack of binding data for the newer AEDs is the fact that most are considered not to be 
bound to serum proteins or indeed are minimally bound and therefore not associated with 
pharmacokinetic variability and consequently lack of clinical significance. 
Because the available protein binding data have been collected during a 62 year period 
(1954-2016) using different methodologies and different methodological conditions, a direct 
comparison between drugs is not possible. We report on the serum protein binding of 25 AEDs, and 
including the pharmacologically active metabolites, carbamazepine-epoxide and  N-desmethyl-
clobazam, using a standard methodology (ultracentrifugation; Amicon Cetrifree Micropartition 
System), under set conditions (i.e. 500 µL serum volume; centrifugation at 1,000g for 15 minutes 
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and at 25°C). This will allow, for the first time, a comprehensive comparison of AED serum protein 
binding. 
 
Materials and Methods 
Study Population 
Data were retrospectively collected from adults attending the specialist epilepsy clinics of 
the National Hospital for Neurology and Neurosurgery (Queen’s Square and Chalfont sites), 
between November 2009 and August 2016 who had serum samples collected for AED 
concentration determination, as part of their routine clinical management. Informed consent was not 
necessary as it only involved data generated as part of routine clinical management. 
The samples selected for inclusion were those that had their total AED concentration 
spanning the quoted reference range for the particular drug. Monotherapy AED samples were 
preferred but most samples contained polytherapy AEDs. To avoid potential protein binding 
displacement interactions that could have skewed the data, sera containing concomitant known 
highly protein bound AEDs (e.g. valproic acid, phenytoin, perampanel and stiripentol) were 
excluded when the drug of interest was itself highly protein bound. In total, the protein binding of 
the various AEDs was undertaken in the sera of 278 subjects. 
 
Sample collection 
Blood samples (6 mL) were withdrawn at times comprising of pre-dose (i.e. time zero 
representing a trough sample) and up to 5 hours post AED ingestion. Sampling occurred during the 
period 09.00-13.00h. After clot retraction blood samples were centrifuged and sera aliquoted into 
plastic 2 mL microcentrifuge tubes and stored at -80°C until analysis for AED content. 
 
Determination of free concentration  
We used an Amicon Cetrifree Micropartition System (Amicon, Stonehouse, UK) to separate 
in serum the non-protein bound fraction of the various AEDs. Serum (500 µL) was placed on the 
filter membrane mounted on the sample reservoir and the tube system was centrifuged for 15 
minutes using a Sigma 2K15 centrifuge (1,000g) with a temperature setting of 25°C. The AED 
concentrations in whole serum and in the filtrate were determined and the free fraction of the drug 
calculated from these values. Free fraction (%) = free concentration/total concentration x 100. 
 
Chemicals 
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Pure AED compounds were purchased from Sigma-Aldrich (Poole, Dorset, UK) but some 
were obtained free-of-charge:   brivaracetam, lacosamide and levetiracetam (UCB, Chemin du 
Foriest, Belgium); zonisamide (Elan Pharmaceuticals, UK); N-desmethyl-clobazam (Roche, 
Welwyn Garden City, UK); felbamate (Schering-Plough, France); tiagabine (Norvo-Nordisk, 
Sweden); pregabalin (Pfizer Ltd, Sandwich, UK);  vigabatrin (Merrell Dow Research, Winnersh, 
UK); gabapentin (Parke Davis, Cambridge, UK); 10-hydroxycarbazepine (Novartis, Basel, 
Switzerland); lamotrigine and retigabine (GlaxoSmithKline, Welwyn Garden City, UK); 
perampanel (Eisai, Japan); rufinamide (Eisai, UK).  
Formic acid (analytical grade), and LC/MS grade methanol and acetonitrile were purchased 
from Sigma-Aldrich (Poole, Dorset, UK). Ultra high quality water was obtained from a Direct-Q 
system (Millipore, Watford, UK).  
 
AED Analysis  
AED free and total concentration analysis was undertaken by LC/MS using fully validated 
methodologies in routine use within our Therapeutic Drug Monitoring Unit. Validation was based 
on the most recent versions of the guidelines on bionalytical method validation of the European 
Medicines Agency and the US Food and Drug Administration. Briefly, an Agilent 1200 series 
automated LC with an Agilent 6400 series triple quad MS (Agilent Technologies, Stockport, 
Cheshire, UK) and a HiQ sil C18 column were used. Sera (24 μL) were extracted with 500 μL 
acetonitrile and prepared for LC/MS analysis by use of a Gilson Quad-Z215 liquid handler (Gilson 
Instrumentation Services, Luton, Bedfordshire, UK). Calibration curve linearity was observed over 
the concentration ranges typically seen in routine clinical practice and which spanned the quoted 
reference range for each AED (Table 4).    
 
Results 
Table 4 provides a summary of the characteristics of the various AEDs in alphabetical order. 
In total, the protein binding of the various AEDs was undertaken in the sera of 278 subjects. For 
each drug, the mean and range of the total and free concentration and the mean percentage free and 
total concentration values are shown. The laboratory reference range for each drug is also shown; 
for most AEDs the serum total concentration measurements were within their depicted laboratory 
reference ranges. The mean protein binding of N-desmethyl clobazam is 89.2%; almost identical to 
that of clobazam (90%). The highly protein bound AEDs (≥ 88%) include clobazam, clonazepam, 
perampanel, retigabine, stiripentol, tiagabine and valproic acid. Only two AEDs appear to be truly 
non-protein bound, gabapentin and pregabalin whilst the minimally bound AEDs (<22%) include 
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ethosuximide (21.8%), lacosamide (14.0%), levetiracetam (3.4%), topiramate (19.5%) and 
vigabatrin (17.1%). Ten of the 26 AEDs can be classified as exhibiting moderate protein binding 
(mean range, 27.7-74.8%). 
The protein binding of valproic acid was determined in the serum of 20 subjects treated with 
sodium valproate in combination with other AEDs. As shown in Figure 1, the valproic acid free 
fraction was higher with high serum total concentrations indicating saturable protein binding of 
valproic acid. However, inter-patient variability in the degree of binding, at any given total 
concentration value, was considerable.    
 
Discussion 
We present the serum protein binding of 25 AEDs that are licensed for clinical use, along 
with two pharmacologically active metabolites, using a standard methodology under set conditions. 
Consequently, these data allow, for the first time, a comprehensive comparison of AED serum 
protein binding. Our data provide interesting findings on the protein binding of AEDs. With regards 
to the first generation AEDs (Table 1), our data overall concur with previous reports; these include 
carbamazepine, carbamazepine-epoxide, clobazam, phenobarbital, phenytoin and valproic acid. The 
89% protein binding of the pharmacologically active metabolite of clobazam, N-desmethyl 
clobazam (Table 4), is the first report of its binding and is almost identical to that of the 90% 
binding of the parent drug, clobazam. For clonazepam, its binding is 90% and similar to clobazam. 
These data are in contrast to the 47% binding of clonazepam previously reported18 using spiked 
human serum albumin and gel filtration and is likely to be due to methodological differences. This 
may also account for the reported binding of primidone. We found that primidone is 33% protein 
bound. A previous study using equilibrium dialysis reported a binding of 22%22 Another study 
using ultrafiltration reported that primidone is 13.7% bound.15    
There has been only one previous report of the protein binding of ethosuximide. In a study 
using a Sephadex column to separate the free from the bound ethosuximide concentration, no 
significant degree of protein binding, was identified although no actual data were provided.19  This 
has lead to the belief that ethosuximide binding is negligible.39 The SPC for ethosuximide states 
that ethosuximide is “not significantly bound”. Using the saliva/serum ratio, an indirect method of 
determining free serum concentration as it is assumed that serum free levels are in equilibrium with 
saliva values, ethosuximide percentage binding has varied between 0 and 5%.17 The present study 
reports a mean percentage bound ethosuximide of 21.8 (Table 4). 
We observed that valproic acid binding is saturable within the clinically occurring 
concentration range so that its pharmacokinetics is non-linear (Figure 1). Additionally, considerable 
Page 9 of 15 
 
inter- and intra-patient variability in free valproic acid fraction was observed and all these data are 
in line with previous reports.10,12 Due to the changing and unpredictable relationship between total 
and free concentrations, it would be more rational if valproic acid was monitored by measurement 
of the free drug.  
The protein binding of valproic acid appears to be dependent on sample storage and 
incubation temperature. Free fatty acid concentrations progressively increase with time and this 
results in a parallel increase in the valproic acid free fraction.  In a study whereby samples were 
incubated at temperatures varying 4-37°C, at 4°C and room temperature, the increase in free drug 
fraction was relatively small (18 and 25% at 24h) whereas at 37° it was 22, 34 and 86% at 4, 8 and 
24 hours.40 This time-dependent change in binding capacity may lead to an overestimation of the 
actual free concentration in vivo. Samples stored at -20°C are stable with no change in either free 
fraction or free fatty acid concentrations for up to 6 weeks.11 These considerations did nor pertain in 
the present study as samples were stored at -70°C and analyzed within 6 weeks of collection. From 
a practical point of view, if samples are kept refrigerated and the determination of the free fraction 
is performed within 8 hours of blood withdrawal, changes in valproic acid binding capacity are 
relatively small. Methodology and sample handling appears to be critical in measurement of 
valproic acid free fraction, it is therefore not surprising that there is wide variability in reported 
values where disparate methodologies were used (Table 1).  
With regards to the second generation AEDs (Table 2), data on the binding of felbamate, 
gabapentin, pregabalin, tiagabine and vigabatrin are sparse and the only data available are those 
reported in SPCs, which lack details as to methodology or methodology conditions, and their 
binding is stated to be 22-25%, not bound, not protein bound, ~96% and negligible binding, 
respectively. We found that felbamate is 47.8% bound, tiagabine 97.8% and vigabatrin 17.1%; 
pregabalin and gabapentin were not bound. These values are broadly comparable with those quoted 
in the SPCs.  
Previous reports of lamotrigine serum protein binding in vivo, as per saliva/serum 
distribution ratio, was 46-56%.17  We found a mean percentage bound lamotrigine of 65.7 (Table 4). 
A healthy volunteer study of four adults, using ultrafiltration (Amicon Micropartition 
system; temperature not stated), reported that levetiracetam did not bind to serum proteins to any 
significant extent. It was stated that binding was <1% in all subjects at 1 hour after drug ingestion 
and <1% (subject 1), 3% (subject 4) and 6% (subjects 2 and 3) at 12 hours after administration.28 
These data are in line with what we found whereby levetiracetam mean percentage bound 
concentration was 3.4 (Table 4).    
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A study of 17 subjects with epilepsy used three different methods to investigate the protein 
binding of 10-hydroxycarbazepine (the pharmacologically active metabolite of oxcarbazepine): 
equilibrium dialysis (37°C), ultrafiltration (EMIT free level system-SYVA; ambient temperature) 
and saliva/serum ratios.29 Despite the disparate methodologies and conditions, 10-
hydroxycarbazepine binding by the three methods was almost identical and was respectively (mean 
± sd) 40 ± 4%, 45 ± 8% and 41 ± 12%. Furthermore, these data concurred with that of a study of six 
people with trigeminal neuralgia whose 10-hydroxycarbazepine binding was 39.0±6.0.30 The SPC 
quotes a value of ~40%.     
In a review,31 it was noted that topiramate was 9-17% protein bound and the SPC states a 
binding of 13-17% whilst saliva/serum ratio data report topiramate binding to range 0-37%.17 
Noteworthy is that there is a low capacity binding site for topiramate in/on erythrocytes that is 
saturable above serum concentrations of 4 mg/L (Topamax – SPC). We report a mean percentage 
bound topiramate of 19.5 (Table 4). 
Zonisamide protein binding was investigated using ultrafiltration (Amicon microparitition 
system; temperature not stated) in six health volunteers and a mean ± sd binding of 39.4 ± 1.2 was 
observed32 and this concurred with a value of 40-50% quoted in the SPC. Using the same 
methodology as in this previous study and at a temperature of 25°C, we found a mean percentage 
binding of 43.7 (Table 4).    
There is almost no binding data for the third generation AEDs (Table 3). Indeed for 
brivaracetam (≤ 20%), retigabine (~80%) and stiripentol (99%) the only data available are those 
reported in SPCs.  We found binding of 35% for brivaracetam, 88% for retigabine and 96% for 
stiripentol and these data are overall comparable with those quoted in the SPCs.  
The protein binding of eslicarbazepine is reported in the SPC to be <40% whilst 
eslicarbazepine binding is stated in a review to be 30%.33 Neither publication states the 
methodology used. We found a mean percentage bound eslicarbazepine of 43.8 (Table 4). 
   The SPC for lacosamide, which does not stipulate methodological details, reports that 
lacosamide binding to serum proteins is <15%. In contrast, a study using microfiltration (Amicon 
Centrifree Micropartition system) with centrifugation at 25°C,  observed that protein binding in 
serum collected from 48 subjects with epilepsy was 91±4% whilst that calculated from saliva 
measurement was 87 ± 4%.34 Using saliva/serum concentration ratio data, a study reported that 
lacosamide was 2% protein bound after tablet ingestion whilst binding was 9% after syrup 
administration; overall, therefore the value was considered to be <10%.36  We observed a mean 
percentage bound lacosamide of 14.0 (Table 4) and is in accord with that of the SPC and the data 
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from other studies35,36 but in contrast to another.34 The disparate results of this study34 are 
perplexing as the same methodology used in the present study was used.  
In a review37, it was reported that perampanel in vitro plasma protein binding ranged 95-
96% (data provided by Eisai). These data are in line with that of ~95% binding quoted in the SPC. 
The present study reports a mean percentage bound perampanel of 97.6 (Table 4). 
Lastly, in an extensive review38, it was reported that rufinamide “in vitro protein binding to 
albumin ranges 26.2- 34.8%” – these data are referenced as “Eisai data on file” and are in line with 
that of 34% binding quoted in the SPC. The present study reports a mean percentage bound 
rufinamide of 27.7 (Table 4). 
 The ultrafiltration methodology used to prepare the free fraction of the different AEDs in the 
present study needs mention.  Ultrafiltration is considered to be the method of choice in clinical 
laboratories which provides a routine TDM service and this is indeed the practice choice within our 
TDM Unit; its key feature is convenience of use.4 Ultrafiltration requires care as a number of 
factors can impact on the concentration measurement.7,8 In an extensive study, the effect of different 
temperatures on the protein binding of phenytoin (n=131), carbamazepine (n=121) and 
phenobarbital (n=36) taken as monotherapy was assessed.8 The Amicon Centrifree Micropartition 
system was used and centrifugation was for 20 minutes at 1,000 g. The free fraction of all three 
AEDs was observed to be temperature dependent: for phenytoin the mean value was 0.1 (25°C) and 
0.15 (37°C); for carbamazepine the mean value was 0.26 (25°C) and 0.30 (37°C); and for 
phenobarbital the mean value was 0.60 (25°C) and 0.63 (37°C). Interestingly, a previous study 
using the technique of ultrafiltration investigated the effect of temperature (4°C, 26°C and 40°C) on 
the protein binding of phenobarbital observed no significant effect and subsequently undertook all 
further experiments at room temperature and reported that phenobarbital is 40% bound.20 We report 
a mean percentage bound phenobarbital of 47.8 and is in line with essentially all previous reports 
(Table 4). It was reported that the unbound fraction of phenytoin was 0.073 ± 0.007 at 25°C and 
0.117 ±0.008 at 37°C when studied by equilibrium dialysis and this concurs with subsequent 
findings.8  
Other variables that can impact on free fraction measurements is that of diurnal rhythms of 
drug distribution. For example, a study of 12 subjects with epilepsy using ultrafiltration (Millipore 
Corp, Freehold, NJ; temperature not stated) in which samples from different times of the day were 
used found that valproic acid free drug (%) was 10.6 ±1.4 in the morning; 12.6 ±2.2 in the afternoon 
and 12.0 ±2.3 in the evening. Similar diurnal oscillations were observed for phenytoin, primidone, 
phenobarbital and carbamazepine.15 
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Conclusion 
We report on the serum protein binding of 25 currently available AEDs using a standard 
methodology under set conditions. The pharmacologically active metabolites, carbamazepine-
epoxide and N-desmethyl-clobazam were also included and these data allow, for the first time, a 
comprehensive comparison of AED protein binding. The AEDs can be divided into those that are 
highly protein bound (≥ 88%) and include clobazam, clonazepam, perampanel, retigabine, 
stiripentol, tiagabine and valproic acid. Gabapentin and pregabalin are non-protein bound whilst the 
minimally bound AEDs (<22%) include ethosuximide (21.8%), lacosamide (14.0%), levetiracetam 
(3.4%), topiramate (19.5%) and vigabatrin (17.1%). Ten of the 25 AEDs can be classified as 
exhibiting moderate protein binding (mean range, 27.7-74.8%). 
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Figure 1 legend: 
 
Unbound valproic acid fraction (%) as a function of the total serum concentration in 20 patients 
with epilepsy receiving multiple antiepileptic drug (AED) therapy with sodium valproate. Patients 
co-prescribed highly protein bound AEDs were excluded from this comparison and thus the 
potential for protein binding displacement interactions was not a consideration.   
